Your session is about to expire
← Back to Search
Gabapentin + Oxcarbazepine for Neuropathic Pain
Study Summary
This trial is testing whether gabapentin or oxcarbazepine are effective in reducing pain for pediatric patients with neuropathic pain, and whether either drug is better than the other.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 4 trial • 88 Patients • NCT03012815Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I only suffer from chronic headaches.My pain is moderate to severe currently.I have used anticonvulsants for pain management before.I have a condition where my body secretes too much of a hormone that controls urine production.I have a diagnosis related to severe nerve pain or injury.My child can speak and write English as expected for their age.I only have abdominal pain.I have seizures that are not controlled by medication.I am between 8 and 18 years old and have chronic pain due to a nerve injury.
- Group 1: Gabapentin
- Group 2: Placebo
- Group 3: Oxcarbazepine
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this research project open to people who are middle-aged?
"Eligibility for this clinical trial is based on age, with potential participants requiring to be aged between 8-18 years old."
What conditions does Gabapentin typically treat?
"Gabapentin is effective in treating neuralgia, epilepsies, and postherpetic neuralgia."
If a patient wanted to enroll today, would they be able to join the trial?
"This research is not currently enrolling patients. However, it is still listed on clinicaltrials.gov and was last updated on August 5th, 2022. There are 166 other studies concerning neuralgia that are actively recruiting participants as well as 28 trials for Gabapentin specifically."
How many test subjects are needed for this experiment?
"Unfortunately, this trial is no longer enrolling patients. The study was first posted on 10/1/2022 and was last updated on 8/5/2022. However, there are 166 other trials for neuralgia and 28 for Gabapentin that are still admitting patients."
Who meets the requirements to participate in this research project?
"This clinical trial is looking for 60 participants aged 8-18 who currently suffer from neuralgia. In addition to meeting this criteria, patients must also have moderate to severe pain (ranging from 4-10 in a numeric pain rating scale), be able to utilize an interpreter if needed, and have one of the following eligible diagnoses: Complex Regional Pain Syndrome, Fibromyalgia, Lumbar Radiculopathy, Spinal cord injury, Erythromelalgia, Small Fiber Neuropathies, Traumatic or Post-surgical Peripheral Nerve or Plexus Injuries, and Extremity Pain with severe pain"
Does Gabapentin put patients at risk for any adverse health conditions?
"We believe that Gabapentin is safe to use because it has gone through Phase 3 trials. This means that not only is there some evidence supporting its efficacy, but also that multiple rounds of testing have confirmed its safety."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger